Ignite Creation Date:
2025-12-24 @ 11:04 PM
Ignite Modification Date:
2026-01-04 @ 6:43 AM
Study NCT ID:
NCT01345669
Status:
TERMINATED
Last Update Posted:
2017-12-07
First Post:
2011-04-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Sponsor:
Boehringer Ingelheim
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-10-17
Start Date Type:
ACTUAL
Primary Completion Date:
2016-09-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-09-12
Completion Date Type:
ACTUAL
First Submit Date:
2011-04-28
First Submit QC Date:
None
Study First Post Date:
2011-05-02
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-08-17
Results First Submit QC Date:
None
Results First Post Date:
2017-10-23
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-11-03
Last Update Post Date:
2017-12-07
Last Update Post Date Type:
ACTUAL